NKMAX Co., Ltd.
Develops NK cell-based therapies, diagnostics, and biological products.
182400 | KO
Overview
Corporate Details
- ISIN(s):
- KR7182400002
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 분당구 돌마로 172 정자동, 헬스케어혁신파크 1층및6층, 성남시
- Website:
- https://nkmax.com/
- Sector:
- Manufacturing
Description
NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-12-15 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2022-12-14 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 115.6 KB | ||
| 2022-11-14 00:00 |
분기보고서 (2022.09)
|
Korean | 1.1 MB | ||
| 2022-10-17 00:00 |
전환가액의조정
|
Korean | 10.6 KB | ||
| 2022-08-22 00:00 |
투자판단관련주요경영사항(HER2 양성의 국소적으로 진행된 절제불가능 또는 전이성 위암 환자를 대상으로 트라스투주맙/XP와 병용 투여하는 SNK…
|
Korean | 10.3 KB | ||
| 2022-08-19 00:00 |
불성실공시법인미지정(지정유예)
|
Korean | 6.6 KB | ||
| 2022-08-16 00:00 |
반기보고서 (2022.06)
|
Korean | 1.2 MB | ||
| 2022-07-26 00:00 |
불성실공시법인지정예고(공시불이행 2건)
|
Korean | 6.1 KB | ||
| 2022-07-15 00:00 |
전환가액의조정
|
Korean | 10.2 KB | ||
| 2022-06-30 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.7 KB | ||
| 2022-06-30 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 118.2 KB | ||
| 2022-06-28 00:00 |
투자판단관련주요경영사항(티로신키나아제 저해제(TKI) 치료에 실패한 국소 진행성 또는 전이성 비소세포폐암 환자를 대상으로 젬시타빈/카보플라틴 …
|
Korean | 11.0 KB | ||
| 2022-06-20 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.5 KB | ||
| 2022-06-20 00:00 |
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.3 KB | ||
| 2022-06-17 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 23.9 KB |
Automate Your Workflow. Get a real-time feed of all NKMAX Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NKMAX Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NKMAX Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
